| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 09/29/2005 | WO2005018567A3 Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
| 09/29/2005 | WO2005018556A3 Hydroxylamine substituted imidazo-containing compounds |
| 09/29/2005 | WO2005009398A3 Tetracyclic benzamide derivatives and methods of use thereof |
| 09/29/2005 | WO2005009382A3 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| 09/29/2005 | WO2005009340A3 Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith |
| 09/29/2005 | WO2005007107A3 Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| 09/29/2005 | WO2005000244A3 Methods and compositions for treating rheumatoid arthritis |
| 09/29/2005 | WO2004089302A3 Posh polypeptides, complexes and related methods |
| 09/29/2005 | WO2004084843A3 Inhibitors of cathepsin s |
| 09/29/2005 | WO2004073609A3 Posh associated kinases and related methods |
| 09/29/2005 | WO2004069196A3 Novel compounds |
| 09/29/2005 | WO2004014314A3 Methods and compositions concerning poxviruses and cancer |
| 09/29/2005 | US20050215637 Tuberculosis treatment |
| 09/29/2005 | US20050215630 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha |
| 09/29/2005 | US20050215625 Combination therapy for anticoagulation |
| 09/29/2005 | US20050215565 Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents |
| 09/29/2005 | US20050215475 Transmucosal delivery of peptides and proteins |
| 09/29/2005 | US20050214780 Using polymorphism in potassium channel interacting protein (KChIP1) as diagnostic indicator for pancreatic disorders |
| 09/29/2005 | US20050214771 Methods for identifying risk of breast cancer and treatments thereof |
| 09/29/2005 | US20050214329 Vaccine |
| 09/29/2005 | US20050214300 Methods for treating cancer using Porimin as a target |
| 09/29/2005 | US20050214283 Antibodies to CD44 glycoforms and uses thereof |
| 09/28/2005 | EP1578991A2 Methods of diagnosing & treating diabetes and insulin resistance |
| 09/28/2005 | EP1578784A2 Peptides that bind to the vegfr-2 |
| 09/28/2005 | EP1578743A2 Antibacterial agents |
| 09/28/2005 | EP1578719A2 Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| 09/28/2005 | EP1578717A2 Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain |
| 09/28/2005 | EP1578480A2 Antagonists for human prolactin |
| 09/28/2005 | EP1578461A2 Vaccines against hiv-1 tat protein to generate neutralizing antibodies |
| 09/28/2005 | EP1578446A2 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 09/28/2005 | EP1578439A2 Low dose methods for treating disorders in which tnf-alpha activity is detrimental |
| 09/28/2005 | EP1578431A2 Fat regulation |
| 09/28/2005 | EP1578429A2 Protease inhibitors |
| 09/28/2005 | EP1578428A2 Treating alcohol and or substance abuse by antagonizing alpha a2 drenergic receptors with weak dopamine blocking |
| 09/28/2005 | EP1578407A2 Fast dissolving films for oral administration of drugs |
| 09/28/2005 | EP1578403A2 Modified release compositions of milnacipran |
| 09/28/2005 | EP1578399A2 Methods for rapid identification of pathogens in humans and animals |
| 09/28/2005 | EP1578396A2 Methods and compositions concerning poxviruses and cancer |
| 09/28/2005 | EP1578393A2 Primary rat hepatocyte toxicity modeling |
| 09/28/2005 | EP1578385A2 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| 09/28/2005 | EP1578378A2 Absolute quantitation of nucleic acids by rt-pcr |
| 09/28/2005 | EP1578375A2 Boron coated straw neutron detector |
| 09/28/2005 | EP1578374A2 Escape mutants of newcastle disease virus as marker vaccines |
| 09/28/2005 | EP1578369A2 Screening strategy for anticancer drugs |
| 09/28/2005 | EP1578366A2 Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| 09/28/2005 | EP1578364A2 Compositions and methods for the treatmentof immune related diseases |
| 09/28/2005 | EP1578363A2 Novel druggable regions in set domain proteins and methods of using the same |
| 09/28/2005 | EP1578357A2 Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases |
| 09/28/2005 | EP1578325A2 Stable topical drug delivery compositions |
| 09/28/2005 | EP1575520A3 A process for preparation of an agglutination reagent for rapid detection of typhoid |
| 09/28/2005 | EP1263401B1 Oral composition comprising 2'-hydroxypropiophenone |
| 09/28/2005 | EP1008344B1 New dicaffeoylquinic acid derivatives and their use for treating hepatitis b |
| 09/28/2005 | CN1675543A Method for assaying compounds or agents for ability to decrease the activity of microsomal prostaglandin E synthase or hematopoietic prostaglandin D synthase |
| 09/28/2005 | CN1674955A Selective plasma exchange therapy |
| 09/28/2005 | CN1674936A Treatment of MS with goat serum |
| 09/28/2005 | CN1674935A Biofunctional CpG or oligo-/polynucleotide and toxin or enterotoxin containing composition |
| 09/28/2005 | CN1674883A Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| 09/28/2005 | CN1674875A Anti-microbial compositions and methods of using same |
| 09/28/2005 | CN1672688A Medical composite chitinamine gel |
| 09/28/2005 | CN1672683A Hyperlipidemia treating composition |
| 09/28/2005 | CN1220496C Bougie for treating virus hepatitis and preparing method thereof |
| 09/27/2005 | US6949681 Intermediate for preparing glycopeptide derivatives |
| 09/27/2005 | US6949571 Novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. |
| 09/27/2005 | US6949569 Dual molecules containing a peroxide derivative, synthesis and therapeutic applications thereof |
| 09/27/2005 | US6949525 In particular the treatment of osteochondral lesions associated with osteoarthritis by means of intraarticular application of a mixture of hyaluronate and chondroitin sulfate |
| 09/22/2005 | WO2005058235A3 Methods using sulodexide for the treatment of bladder disease |
| 09/22/2005 | WO2005046594A3 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| 09/22/2005 | WO2005046567A3 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same |
| 09/22/2005 | WO2005041869A3 Process for co-spray drying agents with dry silicified mcc |
| 09/22/2005 | WO2005039487A3 Method for early detection of ovarian cancer |
| 09/22/2005 | WO2005037208A3 Nitrone compounds prodrugs and pharmaceutical compositions of the same to treat human disorders |
| 09/22/2005 | WO2005034844A3 Exosite-directed thrombin inhibitors |
| 09/22/2005 | WO2005027830A3 Chimeric transcription factor decoy oligonucleotides |
| 09/22/2005 | WO2005025503A3 A composition and method of treatment for urogenital conditions |
| 09/22/2005 | WO2005023184A3 Antibiotic product, use and formulation thereof |
| 09/22/2005 | WO2005020915A3 Silver dihydrogen citrate compositions comprising a second antimicrobial agent |
| 09/22/2005 | WO2005018580A3 Anti-cancer virus desensitization method |
| 09/22/2005 | WO2005016248A3 A novel antiproliferative factor and methods of use |
| 09/22/2005 | WO2005007069A3 Soft gel formulations for saquinavir |
| 09/22/2005 | WO2005004802A3 N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| 09/22/2005 | WO2004098505A3 Attenuation of ischemia/reperfusion injury |
| 09/22/2005 | WO2004089308A3 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| 09/22/2005 | WO2004078120A3 Collagen compositions and biomaterials |
| 09/22/2005 | WO2004071451A3 Random alkylene oxide copolymers for medical and surgical utilities |
| 09/22/2005 | WO2004060265A3 Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 09/22/2005 | WO2004056316A8 Vaccines against hiv-1 tat protein to generate neutralizing antibodies |
| 09/22/2005 | WO2004047741A3 Modulation of iap-like expression |
| 09/22/2005 | US20050210536 Using vector transformation to brain disorder animal model for use in identifying modulators for treatment and prevention of nervous system, brain and psychological disorders |
| 09/22/2005 | US20050209454 Synthetic process |
| 09/22/2005 | US20050209320 Compounds comprise an androgen receptor (AR) binding moiety which selectively targets the compounds to AR-expressing cancer cells, and a cytotoxic alkylating moiety, such as a nitrogen mustard moiety; (2R)-2-hydroxy-3-[(4-hydroxyphenyl)thio]-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide |
| 09/22/2005 | US20050209285 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs |
| 09/22/2005 | US20050209266 nitrosated 42-deoxy-42-(1H-tetrazol-1-yl)-rapamycin; endothelium-derived relaxing factor (EDRF) agonist; anticoagulant and platelet inhibition agents; restenosis, atherosclerosis, thrombosis; stent coating; minimize interaction between blood and artificial surfaces; mix with nitric oxide donor compound |
| 09/22/2005 | US20050209173 Neurodegenerative protein aggregation inhibition methods and compounds |
| 09/22/2005 | US20050209155 IGF-binding protein-derived peptide or small molecule |
| 09/22/2005 | US20050209128 Statins, especially (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, as nerve conduction velocity or nerve blood flow enhancers in combination with an aldose reductase inhibitor, an ACE inhibitor or an Angiotensin II antagonist |
| 09/22/2005 | US20050208580 Novel protein and method for producing the protein |
| 09/22/2005 | US20050208516 Using beta cell enriched protein (BCEP) concentration as evaluative tool in detection of blood glucose disorders |
| 09/22/2005 | US20050208163 anticholesterol agents contains Persea americana var. drymifolia leaf plant extract; nutraceuticals |
| 09/22/2005 | US20050208162 Esterified fatty acid composition |
| 09/22/2005 | US20050208155 New DNA polymerase inhibitors, mikanolide and dihydromikanolide |